SMMT Profile
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines targeting infectious diseases, with operations in the United States and Latin America. The company is dedicated to addressing significant unmet medical needs through its clinical programs, particularly in the area of Clostridioides difficile infection (CDI). Summit Therapeutics aims to advance treatments that offer enhanced efficacy and safety for patients suffering from challenging infections.
The company's leading product candidate, ridinilazole, represents a breakthrough in antibiotic therapy. Ridinilazole is an orally administered small molecule antibiotic currently in Phase III clinical trials for the treatment of CDI, a severe and often recurrent infection that poses a significant healthcare challenge. Ridinilazole’s development is a key component of Summit Therapeutics' strategy to deliver more effective and targeted treatment options for infectious diseases.
In addition to ridinilazole, Summit Therapeutics is developing SMT-738, an antibiotic designed to combat multidrug-resistant infections, with a particular focus on carbapenem-resistant Enterobacteriaceae (CRE). This class of pathogens is known for its high resistance to multiple antibiotics, making SMT-738 a crucial candidate in the fight against resistant infections. The company is also advancing the DDS-04 series, which aims to address infections caused by Enterobacteriaceae, further expanding its pipeline of innovative therapies.
Founded in 2003 and headquartered in Cambridge, Massachusetts, Summit Therapeutics Inc. has established itself as a leader in the field of antibiotic development. The company’s commitment to advancing new treatments for infectious diseases is supported by its robust clinical research and development programs. By focusing on novel therapies and addressing critical areas of unmet medical need, Summit Therapeutics continues to drive innovation in the biopharmaceutical industry.
|
